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Background: Conflicting data exists on the effectiveness of integrated programs in reducing
recurrent exacerbations and hospitalizations in patients with Asthma and chronic obstructive
lung disease (COPD). We developed a Pulmonologist-led Chronic Lung Disease Program (CLDP)
for patients with severe asthma and COPD and analyzed its impact on healthcare utilization
and predictors of its effectiveness.
Methods: CLDP elements included clinical evaluation, onsite pulmonary function testing,
health education, and self-management action plan along with close scheduled and on-
demand follow-up. Patients with 2 asthma or COPD exacerbations requiring emergency room
visit or hospitalization within the prior year were enrolled, and followed for respiratory related
ER visits (RER) and hospitalizations (RHA) over the year (357  43 days) after CLDP interven-
tions.
Results: A total of 106 patients were enrolled, and 104 patients were subject to analyses. Dur-
ing the year of follow-up after CLDP enrollment, there was a significant decrease in mean RERgency room visits; All-HA, all cause hospitalizations; BNP, Brain Natriuretic Peptide; CHF, congestive
ase Program; COPD, chronic obstructive lung disease; FEV1, forced expiratory volume in first second;
e; ICS, inhaled corticosteroids; LAMA, long acting antimuscarinic agents; LABA, long acting beta ag-
ratory related emergency room visits; RHA, respiratory related hospitalizations; RV, residual volume;
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Impact of an integrated program in asthma and COPD 1795(0.56  1.48 versus 2.62  2.81, p < 0.0001), mean RHA (0.39  0.08 versus 1.1  1.62,
p < 0.0001), and 30 day rehospitalizations (0.05  0.02 versus 0.28  0.07, p < 0.0001). Reduc-
tion of healthcare utilization was strongly associated with GERD and sinusitis therapy, and was
independent of pulmonary rehabilitation. Direct variable cost analyses estimated annual sav-
ings at $1.17 million. Multivariate logistic regression analysis revealed lack of spirometry uti-
lization as an independent risk factor for severe exacerbations.
Conclusions: A Pulmonologist-led disease management program integrating key elements of
care is cost effective and significantly decreases severe exacerbations. Integrated programs
should be encouraged for care of frequent exacerbators of asthma and COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Asthma and COPD affect an estimated 64 million and 235
million people respectively, worldwide [1e3]. While COPD
alone accounts for nearly 800,000 hospitalizations and
estimated $50 billion in healthcare expenditures, asthma
adds another $56 billion in healthcare costs [1,3]. Given the
significant drain of healthcare resources from severe
obstructive lung disease, the Centers for Medicare and
Medicaid Services have specified financial penalties for
hospitals; directed towards rehospitalization after COPD
exacerbations as part of the Hospital Readmissions Reduc-
tion Program [4].
Several interventions have been studied independently to
reduce healthcare utilization in COPD [4]. Few studies have
investigated combined interventions for obstructive lung
disease in the setting of an integrated disease management
program. There is however significant heterogeneity in the
reported components of the program; and lack of structured
program outline that can be adopted in practice [5]. Recent
data investigating disease management programs have re-
ported conflicting outcomes. Rice et al. implemented a
simple program using disease education by a respiratory
therapist combined with an action plan, and reported
reduced hospitalization and ED visits in patients with severe
COPD [6]. In contrast, Fan et al. implemented disease edu-
cation by case managers combined with an action plan, and
reported excess mortality in the intervention group [7]. The
trial was aborted prematurely due to elevated all-cause
mortality in the intervention group and found no differ-
ence in the hospitalization rates. Consequently, a recent
systematic review concluded that the evidence base is
inadequate to recommend specific interventions to reduce
rehospitalizations after COPD exacerbations [4]. Similarly,
studies investigating self-management interventions are
heterogeneous and its most effective form and content
remain unclear [8]. For severe asthma, data on role of dis-
ease management programs are limited to none [9e11].
Irrespective, recurrent exacerbations significantly increase
both mortality and morbidity in severe obstructive lung
disease; accounting for substantial healthcare utilization
[5,12e14]. Hence, we sought to determine the impact of an
integrated multidisciplinary program incorporating in-
terventions of proven benefit on healthcare utilization in
severe obstructive lung disease. We report here significant
associations and predictors of program success.Methods
Chronic Lung Disease Program
We modeled a Chronic Lung Disease Program (CLDP) in May
2013 at the Community Regional Medical Center, a 600 bed
community-based academic hospital affiliated with the
UCSF School of Medicine (see Fig. 1). CLDP comprised of a
nurse practitioner, respiratory therapist and health
educator that were dedicated full-time to the program.
Social workers and medical assistants assisted with clinic
work-flow. Case managers monitored patients hospitalized
for asthma and COPD exacerbations to facilitate transition
into the CLDP. Elements of care included: clinical evalua-
tion by nurse practitioner, independent face-to-face visit
for health education (asthma triggers, breathing and
inhaler use techniques), action plan teaching by respiratory
therapists, onsite pulmonary function testing, psychosocial
assessment by social worker, and referrals to Smoking
Cessation and Pulmonary Rehabilitation programs. Initial
visit ranged from 60 min to 120 min, while follow-up visits
ranged from 20 min to 45 min. On-demand “walk-in” visits
were allowed for enrolled patients. Program policies and
education content were developed and directly supervised
by a Pulmonologist, dedicating an average of 4e8 hours per
week. Obstructive lung disease evaluation and therapy was
based on severity and in accordance with current asthma
and COPD treatment guidelines [15,16].Study design and data collection
Referrals were obtained from inpatient and emergency
room. Enrollment criteria specified patients above 18 years
of age with physician diagnosed asthma or COPD; and with
two or more exacerbations that required ER visits or Hos-
pitalizations in the 12 months prior to referral. All patients
received CLDP interventions and were followed prospec-
tively for 1 year (after program enrollment) for respiratory
related emergency room visits (RER) or respiratory related
hospitalizations (RHA), where the primary diagnosis was
related to an exacerbation of asthma or COPD. All cause
(irrespective of the presenting complaint or primary diag-
nosis) emergency room visits (All-ER) and hospitalizations
(All-HA) were monitored. ER visits and hospitalizations over
the year prior to program enrollment were assessed via
Figure 1 Pulmonologist-led integrated lung disease program model.
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mographics, risk factors, respiratory medication usage, and
diagnostic data in the 12 months prior to and after enroll-
ment in the CLDP were collected and entered into a
secured database for analyses. Study was reviewed and
approved by the Institutional review board committee of
the Community Medical Centers (IRB approval #2013077).Analyses
Sample size power calculations: We hypothesized that the
mean RER and RHA would decrease by 30% post CLDP in-
terventions. Assuming a statistically significant change in
the mean RER and RHA, and using a one-sided paired t test
at a significance level of 0.025 and 80% power; the required
sample size was calculated to be 80 patients. We chose to
enroll a minimum of 100 patients.
Statistical analyses were conducted (SPSS software,
Version 22, IBM ) to compare means of annual visits using
paired sample t-test. Univariate analyses were performed
to determine associations of independent interventions
(pre and post-program enrollment) with effectiveness of
the program in reducing healthcare utilization. Chi-square
tests were used for exact measures of association. A two-
sided Fisher exact p-value is reported for all intervention
analyses. A p-value of <0.05 was considered significant for
all analyses. Multivariate binary logistic regression analyses
were performed to determine independent predictors of
effectiveness of CLDP.
Cost analysis: Patients were assigned costs based on the
relative resource consumption of each visit. For these an-
alyses, variable costs were used to evaluate any potential
cost savings. By taking the variable costs assigned to these
patients via charge codes, the total variable cost perencounter was evaluated. Within this study, the variable
costs were composed of salaries (75%), supplies (12%), drugs
(6%), and miscellaneous other expenses (7%). The relative
percentages of these costs did not vary significantly be-
tween each of the encounter types (ER versus inpatient),
nor did they change significantly between periods (Pre and
Post CLDP enrollment).Results
Baseline characteristics
One hundred and six patients with severe asthma and COPD
(meeting enrollment criteria) were enrolled over 3 months
(May through July of 2013) into CLDP, and followed for a
mean of 357  43 days following enrollment. Two patients
withdrew from the program during this time and were
excluded from the analyses. There were total of three
deaths during the year of follow up. All three patients
(mean forced expiratory volume in first second (FEV1) of
1.3 L, 43% predicted) had been subject to CLDP palliative
interventions and enrolled in hospice care with eventual
death (day 56, day 197 and day 315 after enrollment).
Baseline characteristics of the 104 patients subject to
analysis are shown in Table 1. There were 53 patients with
asthma (and 51 patients with COPD) with a baseline FEV1 of
1.92  0.81 L, and mean residual volume (RV) of 146  51%
of the predicted value along with a mean RV/TLC (Total
Lung capacity) ratio of 47  12. Patients had a mean of
3.75  3.64 asthma or COPD exacerbations (requiring ER
visit or hospitalization) in the year prior to enrollment.
Thirty eight of the 104 patients were active smokers. Major
co-morbidities included history of sinusitis, gastroesopha-
geal reflux disease (GERD), and hypertension in 79%, 61%
Table 1 Baseline characteristics.
Characteristic # Patients (%) Mean  SD
Age (years) 104 54  12
Gender
Male 50 (48%)
Female 54 (52%)
Ethnicity
African American 21 (20%)
Caucasian 33 (32%)
Hispanic 41 (40%)
Other (non-hispanic) 9 (8%)
BMI 33  10
Obstructive lung disease
Asthma 53 (51%)
COPD 51 (49%)
FEV1 e L
(percent predicted)
104 1.92  0.81
(64%  23%)
RV e L (percent predicted) 104 2.8  1.22
(146%  51%)
RV/TLC ratio 104 47  12
Co-morbidities
H/o sinusitis 82 (79%)
H/o GERD 63 (61%)
H/o hypertension 61 (59%)
H/o DM 22 (21%)
H/o OSA 19 (18%)
H/o CHF 13 (13%)
BNP (patients
without H/o CHF)
67 (74%) 35  45
Smoking status
Current 38 (37%)
Nonsmokers (or former) 66 (63%)
Pulmonary
exacerbations (per year)
104 3.75  3.64
Insurance
MISP (county) 49 (47%)
Contract insurance 17 (17%)
Medical 18 (17%)
Medicare 20 (19%)
Figure 2 Effect of CLD program on healthcare utilization:
respiratory related ER visits (RER) and hospitalizations (RHA),
all cause ER visits (All-ER) and hospitalizations (All-HA) in the
12 months prior to (Pre-CLDP) and 12 months after enrollment
in CLDP (Post-CLDP). All changes were statistically significant
(p < 0.01).
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tients had a history of congestive heart failure (CHF). In
patients without history of CHF, mean baseline Brain
Natriuretic Peptide (BNP) was 35  45 (BNP could not be
obtained in 24 patients). All patients had some form of
insurance with 47% of the patients insured through the
Fresno County (MISP, medically indigent services program).
Effect on healthcare utilization
There were a total of 281 RER and 123 RHA in the 12 months
prior to program enrollment (Pre-CLDP). Over the 12
months after enrollment and intervention in the CLD Pro-
gram, these were reduced to 60 RER and 48 RHA. Similarly,
all-cause ER visits and hospitalizations were also signifi-
cantly reduced (499 All-ER visits and 149 All-HA pre-CLDP,
versus 239 All-ER and 105 All-HA post-CLDP, see Fig. 2).
There was a statistically significant reduction in the mean
ER visits and hospitalizations for both respiratory relatedand all-cause events (see Table 2). The mean 30-day res-
piratory related re-hospitalizations were significantly
reduced post-CLDP (0.28 versus 0.05, p < 0.0001). Despite
reduction in overall hospitalization and readmission rates,
there was a statistically significant increase in the mean
length of stay (LOS) for admissions post-CLDP. There was a
statistically insignificant improvement in the mean FEV1
(n Z 48) by 40 ml over the 12 months after CLDP
enrollment.
Effect on variable costs
Total variable costs over the 12 months prior to CLD pro-
gram enrollment were $435,528 for inpatient hospitaliza-
tions (RHA) and $107,728 for RER visits for the hundred and
four patients enrolled in that quarter of the year. After CLD
program interventions, these costs were significantly
reduced to $212,885 for RHA and $36,817 for RER. This
reflected a quarterly total cost savings of $293,555 (See
Table 2).
Associations and predictors of effectiveness
We analyzed differences in independent interventions pre
and post CLDP enrollment to determine the associations
with impact of the CLD program using univariate analyses
(see Table 2). Spirometry utilization, therapy with long
acting antimuscarinic agents (LAMA) and long acting beta
agonists (LABA) was significantly improved post-CLDP.
There was no statistically significant difference in inhaled
corticosteroids (ICS) and home oxygen therapy use post-
CLDP. Therapy of comorbidities (GERD and Sinusitis ther-
apy) was also significantly improved post-CLDP. About 10%
of the patients were referred to and successfully completed
pulmonary rehabilitation program. Multivariate binary lo-
gistic regression analyses revealed Spirometry utilization in
the CLD program to be an independent predictor of
decreased respiratory related ER visits (but not for RHA,
Table 2 CLD program outcomes and associations of independent interventions.
Outcomes Pre-CLDP Post-CLDP p value
RER (mean visits  SD) 2.62  2.81 0.56  1.48 <0.0001
RHA (mean hospitalizations  SD) 1.10  1.62 0.39  0.08 <0.0001
All-ER (mean visits  SD) 4.75  5.45 2.25  3.46 <0.0001
All-HA (mean hospitalizations  SD) 1.40  2.13 1  2.05 0.034
FEV1 (mean  SD) 1.78  0.80 1.82  0.77 0.445
Length of stay (mean days  SD) 3.21  2.57 4.06  3.62 <0.0001
30 Day re-admits (mean admissions  SD) 0.28  0.07 0.05  0.02 <0.0001
Quarterly total direct costs: (RER/RHA, dollars) $543,256 $249,701
Interventions
Spirometry utilization (# patients with spirometry) 39 (38%) 101 (97%) <0.0001
LABA (# patients treated) 75 (72%) 93 (89%) <0.005
LAMA (# patients treated) 37 (36%) 70 (67%) <0.0001
ICS (# patients treated) 86 (83%) 94 (90%) 0.154
GERD therapy (# patients treated) 39 (38%) 77 (74%) <0.0001
Sinusitis therapy (# patients treated) 32 (31%) 88 (85%) <0.0001
Home oxygen therapy (# patients treated) 18 (17%) 21 (20%) 0.72
Referral pulmonary rehabilitation (# completed) 1 (1%) 10 (10%) <0.01
Table 3 Predictors of reduced respiratory ER visits.
Variable Odds ratio 95% CI p value
Spirometry utilization 2.94 1.03e8.40 0.024*
LABA therapy 1.52 0.36e6.42 0.57
LAMA therapy 0.5 0.18e1.41 0.28
GERD therapy 0.48 0.16e1.44 0.29
Sinusitis therapy 1.84 0.54e6.20 0.50
*p < 0.05.
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sinusitis therapy (Odds ratio 2.94, 95% confidence interval
1.03e8.4, p Z 0.024, see Table 3).
All associations and reduction in parameters of health-
care utilization (RER, RHA, AER, AHA) were independent of
Pulmonary rehabilitation (analyses remained statistically
significant with p < 0.05, when excluding patients subject
to pulmonary rehabilitation, n Z 10).
Discussion
Our data suggest that a Pulmonologist-led integrated pro-
gram that integrates evidence based interventions (rather
than in isolation); effectively reduces preventable emer-
gency room visits and hospitalizations. To our knowledge,
this is the first report analyzing associations and predictors
of success of an integrated program targeted for asthma
and COPD. It is not surprising that a dedicated multidisci-
plinary approach might be necessary for severe asthma and
COPD, both of which are thought to be complex polygenic
diseases with multiple triggers and co-morbidities. We were
encouraged to find that utilization of Spirometry which is
widely recommended but poorly practiced, emerged as an
independent predictor of reduction in exacerbations of
asthma and COPD.
Reducing healthcare utilization in patients with severe
obstructive lung disease is currently a topic of interest.
Recurrent exacerbations and hospitalizations not only in-
crease mortality but also independently cause an acceler-
ated decline in the FEV1 [17,18]. In addition,
hospitalizations cost more than any other component of
care for asthma and COPD [3,19,20]. Having a history of
prior exacerbation was found to be the single most impor-
tant predictor of future exacerbations across all stages of
severity of COPD [21]. In our integrated program model, we
found a significant decrease in ER visits and hospitaliza-
tions. There was however an increase in the LOS suggesting
that patients who do get hospitalized despite CLDPinterventions likely had more severe exacerbations with
increased LOS. Close follow-up and health education in a
clinical setting may be required for successful use and
timely initiation of a self-triggered action plan. In addition
to scheduled follow up soon after administering a self-
triggered action plan, CLDP patients were provided direct
telephonic access during and after hours. This provides a
better understanding and execution of the disease therapy
and action plan, thereby decreasing preventable ER visits
and hospitalizations while allowing for seeking of emer-
gency care when in fact necessary.
Spirometry was underutilized in our study population
prior to enrollment in CLD program (less than 40% of pa-
tients had completed Spirometry pre-CLDP). These data are
consistent with prior reports of spirometry underutilization
[22]. Utilization of spirometry independently predicted
decrease in severe exacerbations requiring ER visits in our
study cohort. These data suggest that establishing universal
spirometry utilization for all patients with asthma and
COPD must be an integral part of any program targeting
reduction in exacerbations. Lack of spirometry utilization
may contribute to not only a lack of recognition of severity
of disease and need for step-up therapies, but may also
mask other comorbidities and triggers. Most patients with
severe asthma and COPD exacerbations have been reported
to have multiple comorbidities and triggers [11,20,23,24]. A
significant proportion of patients in our cohort had GERD
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strongly associated with reduction of healthcare utilization
in our study. This is in accord with recent data implicating
GERD as an independent risk factor for increased frequency
of asthma and COPD exacerbations [11,25]. Taken together,
these data suggest that frequent exacerbators should be
aggressively evaluated and treated for comorbidities and
triggers, specifically GERD and sinusitis. Only 13% of our
cohort had a history of congestive heart failure, even
though 59% had a known history of hypertension. A low BNP
value in majority of the others suggested that the preva-
lence of heart failure in our cohort was fairly low. It is
perhaps more beneficial to incorporate interventions in a
program that are targeted towards identification and
therapy of patient specific comorbidities, when present;
rather than to structure disease-specific interventions
solely.
Recent guidelines and evidence suggest that patients
with frequent exacerbations may benefit from use of LAMA
in both asthma and COPD [16,26]. Addition of LAMA therapy
to ICS and LABA therapy (triple therapy) has been shown to
reduce exacerbations and improve quality of life in patients
with COPD [27]. In our study, we found a strong association
of LAMA (but not ICS) therapy with reduction of healthcare
utilization. Referral to pulmonary rehabilitation program
also showed a strong association with reduction in health-
care utilization, as expected. Despite well-established
effectiveness of pulmonary rehabilitation in reducing
COPD exacerbations, poor referral patterns prevail even in
patients with severe exacerbations. An integrated program
can be expected to improve uptake of existing guidelines
for pulmonary rehabilitation.
Cost effectiveness of the CLD program was assessed
using variable costs (actual costs). Billed charges are
neither accurate nor reflective of actual costs, and there-
fore not analyzed. For the patients enrolled in one quarter,
the net cost savings was $294,000 with an estimated annual
cost saving of $1.17 million. Upfront costs to start such a
program would include salary support for the personnel as
well as space issues and associated costs. Although the
initial costs may appear to be large, the downstream ben-
efits from reduction of resource utilization cannot be
underestimated.
Our study has several limitations. Inherent to the
retrospective cohort study design, it lacks a control group.
The sample size is relatively small, and long term outcomes
beyond a year were not assessed. Congestive heart failure
was under-represented in our cohort limiting generaliz-
ability to patients with co-existent heart failure. Also, our
obstructive lung disease cohort included both asthmatics
and COPD patients into the study. We structured the pro-
gram incorporating evidence based strategies that address
unmet needs of frequent exacerbators of severe obstruc-
tive lung disease (both asthma and COPD), with subsequent
disease specific care dictated by current guidelines [15,16].
This allowed for inclusion of exacerbators of both severe
asthma and COPD; phenotypic differentiation of which can
at times be challenging for the generalist as well as the
specialist. Furthermore, recent data have described an
asthma-COPD overlap phenotype in about 15e20% of pa-
tients with obstructive lung disease (and upto 50% in pa-
tients over age 50 years) [28,29]. Interestingly, patientswith features of both asthma and COPD have been reported
to have increased disease severity and exacerbations [30].
While specific interventions vary for severe asthma and
COPD, we believe that the key components of care in our
CLDP model are likely to benefit patients with both dis-
eases. For an integrated program model with an eventual
goal of delivering high-quality holistic care and thereby
reducing healthcare utilization, a broad patient-centered
approach encompassing frequent exacerbators of both
asthma and COPD seems reasonable. A particular strength
of our study is the robust program structure that included a
dedicated nurse practitioner directly supervised by a Pul-
monologist. We also report data on predictors of success
and a cost-effectiveness analysis for our model. Cost ana-
lyses did not include costs to set up a pulmonary rehabili-
tation program; our CLDP model assumes access to an
independent pulmonary rehabilitation program. While
encouraging, our data should be regarded as a pilot study
which needs further confirmation in a larger randomized
controlled trial with a longer duration of follow up.
In summary, our study demonstrates the effectiveness of
an integrated disease management program modeled for
care of patients with recurrent exacerbations of severe
asthma and COPD. Besides reducing preventable exacer-
bations, it may optimize continuity and transition of care
post-hospitalization by providing a medical home for pa-
tients with both diseases. Further, it may improve utiliza-
tion of spirometry and pulmonary rehabilitation programs.
Pulmonologist-led integrated disease management pro-
grams should be promoted in the care of frequent exacer-
bators of asthma and COPD.
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